▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for MedX Health in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$0.15.
The current consensus among 0 contributing investment analysts is to n/a stock in MedX Health. This rating has held steady since March 2021, when it changed from a Buy consensus rating.
MedX Health Corp., a medical device and software company, develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in Canada, the United States, Europe, Australia, Asia, and Latin America. The company offers SIAscopy, a medical device technology that is used to scan skin for suspicious moles and lesions; and phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market. Its product portfolio includes SIMSYS, a skin analysis system; MoleMate, a non-invasive screening device that is designed for general practitioners and skin specialists; and SIAMETRICS, a skin visualization and measurement technology that allows cosmetic formulators and active ingredient manufacturers to measure and quantify the concentrations of melanin, haemoglobin, and collagen in living human skin. The company also provides rehab laser console systems, dental laser console systems, OraLase portable laser probes, MedX home treatment systems, and rehab portable lasers. In addition, it operates DermSecure telemedicine platform that enables the Web-based operation of SIAscopy scanning technology and allows the company to deploy its technology in networks of third-party locations from which patients' mole and lesion scans can be connected to specialist physicians for remote assessment. The company was founded in 1999 and is headquartered in Mississauga, Canada.